Viking Therapeutics
VKTX
$28.44
-0.77%
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered therapies for metabolic and endocrine disorders, with a pipeline led by VK2735 (a dual GLP-1/GIP receptor agonist being advanced in both subcutaneous and oral formulations for obesity), VK2809 (a thyroid hormone receptor beta agonist for NASH/MASH and dyslipidemia), and earlier-stage assets including VK5211 and VK0214. The company occupies a distinct position as one of the few pure-play, mid-cap challengers in the GLP-1 obesity space, competing on the promise of differentiated oral bioavailability and tolerability against entrenched giants Eli Lilly and Novo Nordisk rather than on commercial infrastructure, which it does not yet possess. The current investor narrative is dominated by the advancement of the oral VK2735 program into Phase 3, the September 2026 disclosure of impressive maintenance-phase clinical data, and a $575 million capital raise that extended the cash runway into 2028 while simultaneously pressuring the shares through dilution. Debate now centers on whether Viking's oral formulation can overcome elevated discontinuation rates and carve out durable share in a market where Lilly's own maintenance strategy and late-stage pipeline remain formidable, making VKTX a high-beta, binary-outcome clinical story rather than a near-term earnings compounder.…
VKTX
Viking Therapeutics
$28.44
Related headlines
Investment Opinion: Should I buy VKTX Today?
Rating: Hold (speculative, catalyst-dependent). The core thesis is that Viking offers a genuine, differentiated oral dual GLP-1/GIP asset (VK2735) with a unanimous 14-analyst Buy consensus and an Oppenheimer $120 target implying roughly 4x upside from $26.84, but the equity is a binary Phase 3 clinical option with zero revenue, a widening -$183.19 million quarterly loss, and a broken chart (-27.99% over one year versus SPY +9.59%). The risk/reward is asymmetric only for investors who can underwrite positive Phase 3 tolerability data and absorb another likely dilution before 2028.
Supporting evidence is mixed but tilts toward patience over accumulation at this price. Positives: $677.81 million of cash and runway into 2028, debt-to-equity of 0.0002, a current ratio of 9.33, and cash per share of $8.13 (roughly 30% of the $26.84 price); a price-to-book of 6.20x that has compressed from 11.07x in Q2 2026 and sits mid-band versus a 1.27x-11.07x historical range; and a consensus 2027 EPS of $1.66 on $1.15 billion of revenue that implies the market is paying only about 2x forward sales for the pipeline. Negatives: R&D expense has roughly quadrupled from $41.39 million (Q1 2025) to $166.80 million (Q3 2026), trailing-twelve-month free cash flow is -$462.63 million, and the September $575 million raise already lifted shares outstanding from 112.32 million to 118.05 million.
The biggest risks that could invalidate the thesis are (1) Phase 3 data showing discontinuation rates that erase the oral differentiation argument, (2) another dilutive raise before commercialization, and (3) Eli Lilly's maintenance strategy and commercial infrastructure limiting Viking's addressable share. This Hold would upgrade to Buy on a decisive reclaim of the $30-$32 shelf alongside clean Phase 3 tolerability data, or if price-to-book compresses toward 4x while the clinical narrative holds; it would downgrade to Sell on a break below the $24.21 October low or any Phase 3 safety/tolerability miss. Valuation verdict: fairly valued to modestly rich on book (6.20x) for a pre-revenue biotech, but cheap on forward sales (~2x 2027 consensus) if the launch materializes — the market is pricing meaningful but not euphoric optimism.
Sign up to view all
VKTX 12-Month Price Forecast
Viking is a high-conviction science story wrapped in a broken chart: the sell side is unanimously bullish and the pipeline is priced at only about 2x forward sales, yet the equity has lost 27.99% over a year against a SPY gain of 9.59% and the September maintenance-data spike to $41.65 fully retraced. The balance sheet ($677.81 million cash, 0.0002 debt-to-equity) removes near-term financing risk, but the -$462.63 million trailing free cash flow and quadrupling R&D spend mean another raise is probable before 2028. The decisive variable is Phase 3 oral VK2735 tolerability — if discontinuation rates stay elevated, the differentiation thesis and the entire premium above the $8.13 cash per share collapse. I would upgrade to bullish on clean Phase 3 data plus a reclaim of the $30-$32 shelf, and downgrade to bearish on a break below $24.21 or any safety/tolerability miss.
Wall Street consensus
Coverage is robust for a mid-cap biotech, with 14 analysts contributing estimates and a consensus that leans decidedly bullish: the institutional ratings feed shows ten recent actions, all of them Buy or Overweight (Canaccord Genuity, Truist Securities, JP Morgan, BTIG, Cantor Fitzgerald, and HC Wainwright), with zero Hold or Sell ratings recorded over the past year. The consensus 2027 EPS estimate of $1.66 and revenue estimate of $1.15 billion imply analysts are underwriting a successful launch trajectory, and Oppenheimer's published $120 target — cited in October 2026 coverage as implying roughly 4x upside — anchors the bullish tail. Against the current $26.84 price, the bullish consensus implies substantial upside, though the precise average target is not disclosed in the provided dataset and should be treated as "Data not available" for calculation purposes; qualitatively, sentiment is unambiguously bullish.
The target dispersion is extreme rather than tight, which is itself the key signal: a $120 high-end target assumes VK2735 captures meaningful oral GLP-1 share, multiple expansion toward large-cap biotech levels, and no further dilution, while the low end of the range (not disclosed, but implied by the stock's 42.54% drawdown and 27.99% one-year decline) prices in Phase 3 failure, elevated discontinuation rates undermining the oral thesis, and competitive displacement by Eli Lilly. The pattern of ratings is notable for its uniformity and staleness — firms have reiterated rather than upgraded, with the most recent actions (Canaccord on October 30, Truist on October 7) simply reaffirming Buy ratings after the $575 million raise and the September data readout. A 14-analyst, all-bullish consensus with a 4x-wide target spread signals high conviction in the science but high uncertainty in the outcome — investors should weight the binary clinical catalyst, not the consensus, as the true driver of returns.
Bulls vs Bears: VKTX Investment Factors
The bear case currently carries stronger near-term evidence: the stock is in a confirmed multi-quarter downtrend with -37.58% relative strength versus SPY, a 42.54% max drawdown, and a fully retraced September spike, while the fundamental picture shows a widening loss (-$183.19 million in Q3 2026) and accelerating R&D spend that will require capital before 2028. The bull case is real but forward-looking — a unanimous 14-analyst Buy consensus, a $120 high target implying 4x upside, $677.81 million of cash, and September maintenance data that produced a +35.7% single-session gap. The single most important tension is whether oral VK2735's Phase 3 data can demonstrate tolerability strong enough to overcome elevated discontinuation rates; if it can, the current 6.20x book multiple and ~2x forward sales look cheap, but if discontinuation persists, the differentiation thesis — and the entire pipeline premium above the $8.13 cash per share — collapses. Until that binary catalyst resolves, the technical and fundamental momentum both favor caution over accumulation.
Bullish
- Unanimous 14-analyst Buy consensus: All ten recorded analyst actions over the past year are Buy or Overweight (Canaccord, Truist, JP Morgan, BTIG, Cantor Fitzgerald, HC Wainwright), with zero Hold or Sell ratings across 14 contributing analysts. Oppenheimer's $120 target implies roughly 4x upside from the $26.84 price, and the consensus 2027 EPS of $1.66 on $1.15 billion of revenue shows the sell side is underwriting a successful launch rather than a binary failure.
- Cash runway secured into 2028: The $575 million raise lifted Q3 2026 cash to $677.81 million and pushed runway into 2028, funding Phase 3 VK2735 trials without near-term financing risk. With debt-to-equity at 0.0002 and a current ratio of 9.33, the balance sheet is essentially unlevered, and cash per share of $8.13 means roughly 30% of the $26.84 price is backed by cash.
- Oral VK2735 differentiation validated: The September 2026 maintenance-phase data readout drove a single-session gap from $30.11 to $40.85 (+35.7%) on September 22, evidence that the oral dual GLP-1/GIP formulation produced clinically meaningful results. Viking remains one of the few pure-play mid-cap challengers in a GLP-1 obesity market where an oral, well-tolerated option could capture share without commercial infrastructure.
- Valuation reset to mid-range book multiple: Price-to-book has compressed from 11.07x in Q2 2026 to 6.20x today, sitting roughly midway through a historical band of 1.27x (Q1 2022) to 11.07x. The market is ascribing only about $2.2 billion to the pipeline against a $1.15 billion 2027 revenue consensus — roughly 2x forward sales for a company with no approved product, a modest option premium rather than euphoria.
Bearish
- Broken chart, severe relative weakness: VKTX is down 27.99% over one year and 24.22% YTD against a SPY that gained 9.59%, a relative strength gap of -37.58%. The 42.54% maximum drawdown and current price at roughly 15% of the 180-day $24.21-$42.13 range confirm persistent distribution, and the September spike to $41.65 fully retraced — a classic failed breakout that caps rallies.
- Burn rate accelerating toward Phase 3 peak: R&D expense rose from $41.39 million in Q1 2025 to $166.80 million in Q3 2026, roughly 4x in eighteen months, while the quarterly net loss widened to -$183.19 million from -$90.79 million a year earlier. Trailing-twelve-month free cash flow is -$462.63 million with Q3 operating burn of -$138.19 million, and the $575 million raise funds runway only into 2028 — another dilution event is probable before commercialization.
- Elevated discontinuation undermines oral thesis: Recent coverage explicitly flags high discontinuation rates for the oral VK2735 formulation as a core risk to the investment case. Because the entire bull thesis rests on oral tolerability differentiating Viking from injectable incumbents, any Phase 3 signal that patients cannot stay on the drug would invalidate the differentiation argument and the $120 bull target built on it.
- Eli Lilly competition and maintenance strategy: Lilly's stock barely moved on Viking's impressive September maintenance data, reflecting that Lilly has its own robust maintenance strategy and late-stage pipeline plus commercial infrastructure Viking lacks. With zero revenue and 74 employees, Viking must win on clinical superiority alone against an entrenched incumbent that can outspend and out-distribute it.
VKTX Technical Analysis
VKTX is locked in a sustained, multi-quarter downtrend, with the shares down 27.99% over the trailing year and 24.22% year-to-date, a stark underperformance against a SPY that gained 9.59% over the same twelve months (relative strength of -37.58%). At the current price of $26.84, the stock sits near the bottom of its 180-day observed range of roughly $24.21 to $42.13, translating to approximately 15% of that range — a positioning that signals persistent distribution and momentum failure rather than a healthy pullback within an uptrend. The 42.54% maximum drawdown confirms this is a broken chart where rallies have been sold, and buyers here are catching a falling knife until proven otherwise.
Short-term momentum remains negative but is decelerating in its rate of decline: the 1-month change of -5.96% and 3-month change of -21.66% show the selling pressure has moderated relative to the sharper mid-quarter collapse, though the 6-month change of -14.33% confirms the damage is structural rather than a brief shakeout. The stock's relative strength versus SPY is negative across every window (-0.97 over 1 month, -16.75 over 3 months, -13.79 over 6 months), meaning even the recent market-wide weakness (SPY -4.99% over 1 month) has been outperformed to the downside by VKTX. Notably, the most recent session printed a +4.07% bounce off the $25.79 prior close on volume of roughly 2.67 million shares, a modest stabilization signal, but one that follows a September spike to $41.65 that fully retraced — a classic failed-breakout pattern that typically caps rallies.
Key technical levels are well defined: support rests at the October low of approximately $24.21, with a secondary shelf near $25.00-$25.50, while resistance is anchored at the $40.85-$41.65 September spike zone and, more immediately, the $30-$32 area where the stock repeatedly stalled in August and September. A decisive break below $24.21 would likely trigger momentum-driven liquidation toward new lows, whereas reclaiming $32 would be the first credible evidence of a trend change. With a beta implicitly elevated by the 42.54% drawdown and the stock's tendency to gap 10%+ on single sessions (the September 22 jump from $30.11 to $40.85), position sizing must assume binary, event-driven volatility far exceeding market averages — this is a name where stop discipline and small allocation sizes are non-negotiable.
Beta
—
—
Max Drawdown
-42.5%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
-30.0%
Cumulative gain past year
| Period | VKTX Return | S&P 500 |
|---|---|---|
| 1m | +0.4% | -2.4% |
| 3m | -13.7% | -2.3% |
| 6m | -6.0% | +2.8% |
| 1y | -30.0% | +11.3% |
| ytd | -19.7% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VKTX Fundamental Analysis
Viking is a pre-revenue clinical-stage company: reported revenue was $0 in each of the last five quarters (Q3 2026 through Q3 2025), so traditional growth metrics are inapplicable and the investment case rests entirely on pipeline progression rather than top-line trajectory. What is growing is the spending base — research and development expense escalated from $41.39 million in Q1 2025 to $166.80 million in Q3 2026, a roughly 4x increase in eighteen months, while total operating expenses rose from $55.47 million to $187.11 million over the same span. This ramp reflects the cost of running Phase 3 obesity trials, and it is the single most important fundamental variable: the burn rate is accelerating precisely as the company approaches its most capital-intensive period.
Profitability is absent by design, with a Q3 2026 net loss of $183.19 million (EPS of -$1.55) versus a net loss of $90.79 million in Q3 2025 — the loss more than doubled year-over-year, and the sequential progression from -$158.33 million (Q1) to -$128.02 million (Q2) to -$183.19 million (Q3) shows no stabilizing trend. Gross margin is 0% and operating margin 0%, as expected for a company with no product revenue; the only offset is interest income, which actually declined from $7.77 million in Q3 2025 to $4.01 million in Q3 2026 despite a larger balance sheet, reflecting lower yields or a shift in the investment mix. Return on equity of -56.28% and return on assets of -18.75% underscore that shareholder capital is being consumed, not compounded, and the relevant benchmark is not industry margin but rather cash runway versus the timeline to a regulatory filing.
Balance-sheet strength is the company's principal financial asset: debt-to-equity is effectively zero at 0.0002, the current ratio stands at 9.33, and cash at the end of Q3 2026 was $677.81 million, bolstered by $346.55 million of common stock issued during the quarter and $597.55 million of net financing inflows. However, free cash flow is deeply negative at -$462.63 million on a trailing-twelve-month basis, with quarterly operating cash burn of -$138.19 million in Q3 2026, and the $575 million raise explicitly extends runway only into 2028 — meaning another financing event is probable before commercialization unless a partnership materializes. The cash-per-share figure of $8.13 against a $26.84 stock price implies roughly 30% of the market cap is cash, providing a valuation floor of sorts, but the negative FCF yield and -$1.17 free cash flow per share confirm the company remains wholly dependent on external capital markets, making it acutely sensitive to both biotech risk appetite and dilution risk.
Quarterly Revenue
$0.0B
2026-09
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-462632000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VKTX Overvalued?
Because Viking's trailing net income is negative (-$183.19 million in Q3 2026 alone) and EBITDA is -$183.10 million, the PE ratio of -11.03 and EV/EBITDA of -10.57 are economically meaningless; with revenue at zero, the PS ratio is also undefined (reported as 0). The appropriate primary metric is therefore price-to-book, currently 6.20x, supplemented by the cash-adjusted framework: with $8.13 of cash per share against a $26.84 price, the market is ascribing roughly $18.71 per share — approximately $2.2 billion — to the pipeline, which must be weighed against a consensus 2027 revenue estimate of $1.15 billion that implies the market is pricing only about 2x forward sales for a company with no approved product. The forward PE of -0.05 and PEG of -0.05 are artifacts of negative earnings and should be disregarded entirely.
Peer comparison is constrained by the absence of a populated industry-average dataset in the provided valuation inputs, but the observable spread is instructive: VKTX trades at 6.20x book versus its own historical book multiples that have ranged from roughly 1.27x (Q1 2022) to 11.07x (Q2 2026), placing the current multiple in the middle of that band. Against large-cap GLP-1 peers such as Eli Lilly, which command premium multiples on realized earnings and commercial infrastructure, Viking's valuation is best characterized as an option premium on pipeline probability rather than a discount or premium on current fundamentals — the 6.20x book multiple is rich for a pre-revenue biotech but defensible if VK2735 reaches market, and unjustifiable if Phase 3 disappoints.
Historical context reinforces the mean-reversion risk in both directions: the price-to-book ratio peaked at 11.07x in Q2 2026 (when the stock traded near $40) and troughed at 1.27x in Q1 2022, so the current 6.20x sits roughly midway through a very wide historical range. The compression from 11.07x to 6.20x over two quarters reflects both the September capital raise (which inflated book value via $346.55 million of stock issuance) and the price decline, meaning the multiple has fallen for a mechanically favorable reason as well as a sentiment-driven one. Investors should treat the current valuation as pricing in meaningful but not euphoric optimism — a reasonable entry only for those who underwrite positive Phase 3 data, with the historical range suggesting 30-50% downside to trough multiples if the clinical narrative breaks.
PE
-11.0x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
29.3x
Industry PE ~29.3x*
EV/EBITDA
-10.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are dominated by a burn rate that is accelerating into the most capital-intensive phase of the company's life. R&D expense climbed from $41.39 million in Q1 2025 to $166.80 million in Q3 2026, and the quarterly net loss widened to -$183.19 million (EPS -$1.55) from -$90.79 million a year earlier, with trailing-twelve-month free cash flow of -$462.63 million and Q3 operating burn of -$138.19 million. The $575 million raise extends runway only into 2028, meaning another financing is probable before commercialization unless a partnership materializes, and the September issuance of $346.55 million of stock already demonstrated the dilution cost — shares outstanding rose from 112.32 million to 118.05 million in a single quarter. Revenue concentration risk is absolute: revenue is $0 across all five recent quarters, so 100% of the equity value depends on a single asset, VK2735, reaching approval. Market and competitive risks center on a valuation with no earnings floor and a stock that has lost 27.99% over one year against a SPY gain of 9.59%, a -37.58% relative strength gap that reflects both biotech risk-appetite compression and company-specific disappointment. The 6.20x price-to-book multiple is rich for a pre-revenue company and sits midway in a historical band of 1.27x to 11.07x, leaving 30-50% downside to trough multiples if sentiment breaks; the stock's tendency to gap 10%+ in single sessions (September 22: $30.11 to $40.85) implies an effective beta far above market averages, and the 42.54% max drawdown quantifies that event-driven volatility. Competitive pressure from Eli Lilly is the key external threat — Lilly's shares barely moved on Viking's September maintenance data because Lilly has its own maintenance strategy, a late-stage pipeline, and commercial infrastructure Viking entirely lacks, and recent coverage of Novo Nordisk's diversification efforts underscores how aggressively incumbents are defending GLP-1 share. The worst-case scenario is a Phase 3 readout showing discontinuation rates that erase the oral differentiation thesis, triggering analyst downgrades from the currently unanimous Buy consensus and a collapse of the pipeline premium. In that chain of events, the stock would likely retest and break the October low of $24.21 and gravitate toward the $8.13 cash-per-share floor plus a minimal pipeline option, implying a realistic downside of roughly -35% to -70% from the current $26.84 — with the 42.54% max drawdown as the observed precedent for how far a sentiment break can carry the shares.
FAQ
Ranked by severity, the first risk is clinical/company-specific: Phase 3 oral VK2735 data showing discontinuation rates that invalidate the differentiation thesis, which would remove the entire premium above the $8.13 cash per share and likely force downgrades from the unanimous Buy consensus. Second is financial: R&D has roughly quadrupled from $41.39 million in Q1 2025 to $166.80 million in Q3 2026, the quarterly loss widened to -$183.19 million, and trailing free cash flow is -$462.63 million, so another dilutive raise before 2028 is probable — shares outstanding already rose from 112.32 million to 118.05 million last quarter. Third is competitive: Eli Lilly's own maintenance strategy, late-stage pipeline, and commercial infrastructure barely budged Lilly's stock on Viking's September data, and Novo Nordisk's diversification efforts show incumbents defending GLP-1 share aggressively. Fourth is market/valuation: a 6.20x book multiple with no earnings floor, a -37.58% one-year relative strength gap versus SPY, and a 42.54% max drawdown mean sentiment breaks can carry the shares 30-50% lower toward trough multiples.
The 12-month outlook splits into three scenarios: a 50% base case of $24-$42, a 25% bull case of $55-$120, and a 25% bear case of $8-$24. The base case is most likely and assumes Phase 3 readouts slip beyond the window or arrive incrementally, R&D stays near the $166.80 million quarterly run-rate, no major partnership materializes, and the stock keeps oscillating within its 180-day range while the $8.13 cash per share provides a partial floor. The bull case requires Phase 3 tolerability data strong enough to neutralize discontinuation concerns, prompting targets to move toward Oppenheimer's $120 and multiple expansion on the $1.15 billion 2027 revenue consensus. The bear case assumes a tolerability miss that breaks the $24.21 October low and drags shares toward the cash floor plus a minimal pipeline option, consistent with the observed 42.54% max drawdown. The key assumption behind the base case is that the binary catalyst does not resolve within twelve months.
Traditional multiples are unusable here: with $0 revenue, a trailing PE of -11.03, EV/EBITDA of -10.57, and a PEG of -0.05, the only meaningful metric is price-to-book at 6.20x. That multiple has compressed from 11.07x in Q2 2026 and sits roughly midway through a historical band of 1.27x (Q1 2022) to 11.07x, so the stock is neither at a historical premium nor a discount. On a cash-adjusted basis, $8.13 per share of cash means the market is paying about $18.71 per share — roughly $2.2 billion — for the pipeline, which is only about 2x the $1.15 billion 2027 revenue consensus if the launch materializes. That implies the market is pricing meaningful but not euphoric optimism: a modest option premium on clinical success rather than a discount to fair value. The verdict is fairly valued to modestly rich on book for a pre-revenue biotech, and cheap on forward sales only if VK2735 reaches market.
From a pure risk/reward standpoint, VKTX offers an unusually wide outcome distribution: Oppenheimer's $120 target implies roughly 4x upside from $26.84, and the unanimous 14-analyst Buy consensus with a $1.66 2027 EPS estimate shows the sell side is underwriting a successful launch. Against that, the stock has lost 27.99% over one year versus a SPY gain of 9.59%, sits at roughly 15% of its 180-day $24.21-$42.13 range, and carries a 42.54% max drawdown with a realistic bear path toward the $8.13 cash-per-share floor. The biggest downside risk is a Phase 3 tolerability miss that erases the oral differentiation thesis and collapses the pipeline premium. It is a good buy only for risk-tolerant investors who can underwrite clean Phase 3 discontinuation data and absorb another probable dilution before 2028, sized as a small speculative position; for most portfolios the evidence supports waiting for data or a reclaim of the $30-$32 shelf rather than accumulating into a downtrend.
VKTX is a pre-revenue clinical-stage company with $0 revenue, a -$183.19 million quarterly loss, and no dividend (payout ratio of 0), so there is no income or earnings-compounding case to hold for yield; the return driver is a single binary Phase 3 catalyst. Its volatility profile is extreme — a 42.54% max drawdown, a 27.99% one-year decline, and single-session gaps such as the September 22 move from $30.11 to $40.85 (+35.7%) — which makes it unsuitable for short-term trading unless the trader is explicitly positioning around data events with strict stop discipline. For long-term investors, the appropriate framing is a multi-year hold through commercialization or partnership, but only with a small allocation that can tolerate a further 30-70% drawdown and probable dilution before 2028. A concrete minimum holding period of 18-24 months is reasonable, spanning the Phase 3 readout and the next financing, with position sizing treated as an option premium rather than a core allocation.